Repurposing of Bromocriptine for Cancer Therapy

Ean-Jeong Seo¹, Yoshikazu Sugimoto², Henry Johannes Greten³ and Thomas Efferth¹*

¹ Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany, ² Division of Chemotherapy, Faculty of Pharmacy, Keio University, Tokyo, Japan, ³ Abel Salazar Institute of Biomedical Sciences, University of Porto, Porto, Portugal

Bromocriptine is an ergot alkaloid and dopamine D₂ receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus. The drug is also active against pituitary hormone-dependent tumors (prolactinomas and growth-hormone producing adenomas). We investigated, whether bromocriptine also inhibits hormone-independent and multidrug-resistant (MDR) tumors. We found that bromocriptine was cytotoxic towards drug-sensitive CCRF-CEM, multidrug-resistant CEM/ADR5000 leukemic cells as well as wild-type or multidrug-resistant ABCB5-transfected HEK293 cell lines, but not sensitive or BCRP-transfected multidrug-resistant MDA-MB-231 breast cancer cells. Bromocriptine strongly bound to NF-κB pathway proteins as shown by molecular docking and interacted more strongly with DNA-bound NF-κB than free NF-κB, indicating that bromocriptine may inhibit NF-κB binding to DNA. Furthermore, bromocriptine decreased NF-κB activity by a SEAP-driven NF-κB reporter cell assay. The expression of MDR-conferring ABC-transporters (ABCB1, ABCB5, ABCC1, and ABCG2) and other resistance-mediating factors (EGFR, mutated TP53, and IκB) did not correlate with cellular response to bromocriptine in a panel of 60 NCI cell lines. There was no correlation between cellular response to bromocriptine and anticancer drugs usually involved in MDR (e.g., anthracyclines, Vinca alkaloids, taxanes, epipodophyllotoxins, and others). COMPARE analysis of microarray-based mRNA expression in these cell lines revealed that genes from various functional groups such as ribosomal proteins, transcription, translation, DNA repair, DNA damage, protein folding, mitochondrial respiratory chain, and chemokines correlated with cellular response to bromocriptine. Our results indicate that bromocriptine inhibited drug-resistant tumor cells with different resistance mechanisms in a hormone-independent manner. As refractory and otherwise drug-resistant tumors represent a major challenge to successful cancer chemotherapy, bromocriptine may be considered for repurposing in cancer therapy.

Keywords: drug repurposing, ergot alkaloids, bromocriptine, neoplasms, pharmacogenomics

INTRODUCTION

Bromocriptine is an ergot alkaloid and dopamine D₂ receptor agonist that has been used to treat Parkinson’s disease by affecting dopamine receptor signaling in the nigrostriatal tract and to treat hyperprolactinemia and acromegaly through tuberoinfundibular pathways (Kvernmo et al., 2006). It showed inhibitory effects on serotonin turnover in the central nervous system (CNS; Goldstein, 1980).
Glucose and energy metabolism is tightly regulated by the CNS in the medial basal hypothalamus (Sandoval et al., 2008). The CNS regulates hepatic glucose production through sympathetic pathways and integrates information via leptin, ghrelin, insulin, glucagon-like peptide-1 (GLP-1), and other hormonal signals. Diabetic and obese patients have damaged responses to these signal pathways and increased hepatic glucose production, insulin resistance, and impaired pancreatic β-cell function (Defronzo, 2009). A reformulation of bromocriptine for type 2 diabetes was investigated and approved for clinical use (Pijl et al., 2000). The treatment of bromocriptine decreased body weight and improved glucose tolerance in obese people (Cincotta and Meier, 1996). Furthermore, it decreased body fat stores, improved glycemic control, and reduced the need for oral hypoglycemic agents in obese patients with type 2 diabetes (Meier et al., 1992).

Bromocriptine was introduced on the market in 1973 and was used for more than 40 years (Weil, 1986). It is administered at daily doses of 1.25–80 mg against pituitary hormone-dependent tumors (mainly from prolactinomas and growth-hormone producing adenomas) and at daily doses of 3.75–170 mg against Parkinson’s disease (Weil, 1986). Bromocriptine normalizes prolactin and reduces tumor mass in 80–90% of patients with microadenomas and in 70% of patients with macroadenomas (Casanueva et al., 2006). Long-term bromocriptine treatment has no harmful effects on hepatic, renal, hematologic, or cardiac functions (Weil, 1986).

Remarkably, bromocriptine’s bioactivities are even broader. It exerts inhibitory effects against Chagas disease, which is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi. Bromocriptine inhibited the cysteine protease cruzipain and thereby the growth of T. cruzi (Bellera et al., 2013).

Drug repurposing is the application of known drugs and compounds for new indications. The interest in this approach is based on the fact that already approved drugs do not need the long and costly development of new drugs to obtain the approval to treat a disease (Ashburn and Thor, 2004). Bromocriptine is widely used against Parkinson’s disease for more than 30 years and has been repurposed for the treatment of diabetes. Therefore, it is worth to investigate, whether bromocriptine could be also developed for other diseases.

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) has a key role in inflammation. It induces the expression of pro-inflammatory and proliferative interleukins (ILs), tumor necrosis factor (TNF), interferons, and cyclooxygenases on the response to carcinogens, growth factors, and inflammatory stimuli. The NF-κB complex contains the p50 and p65 subunits. Inactive NF-κB binds IκBα, which is one member of a family of cellular proteins that inhibit NF-κB. The activation of IκB kinase (IκK) complex [IκK-α and IκK-β associated with NF-κB essential modulator (NEMO)] can be induced by binding of ligands to their receptors. NF-κB is an important factor for cell proliferation and cancer progression (Dhanalakshmi et al., 2002; Hayden and Ghosh, 2008).

Bromocriptine was reported to reduce hepatic lipid levels and insulin resistance, which are linked suppressed hyperleptinemia and inhibition of transcription factors and enzymes for lipogenesis and gluconeogenesis, as well as signaling proteins such as suppressor of cytokine signaling 3 (SOCS3), and Jun N-terminal kinase (JNK; Ezrokhi et al., 2014).

Bromocriptine inhibited prolactin-secretion resulting in suppression of lactation and bound to dopamine D2 receptor (Radaj et al., 2005). Prolactin exerts both behavioral effects in the brain (Torner et al., 2001; Brunton and Russell, 2010). It induced NF-κB (Rivero-Segura et al., 2017) and exerted antioxidant properties by scavenging free oxygen radicals both in vitro and in vivo (Yoshikawa et al., 1994; Muralikrishnan and Mohanakumar, 1998). Increased antioxidant action is one of the most important ways to affect NF-κB (Morgan and Liu, 2011).

In our study, we addressed the question whether bromocriptine is not only active against hormone-dependent tumors but also might exert cytotoxic activity against cancer cells in a hormone-independent fashion. As tumors frequently develop resistance to anticancer drugs, we investigated, whether or not multidrug-resistant (MDR) cells expressing either the ATP-binding cassette (ABC) transporter P-glycoprotein (ABCBI and MDR1) or ABCB5 exert cross-resistance to bromocriptine. Furthermore, microarray-based mRNA expression data were applied to COMPARE and hierarchical cluster analyses to identify gene expression profiles that correlated with sensitivity or resistance of a panel of 60 tumor cells lines of the National Cancer Institute (NCI), United States, to bromocriptine. Moreover, we investigated the inhibitory effect of bromocriptine toward NF-κB using in silico molecular docking and NF-κB reporter cell assay, since several studies showed that bromocriptine affects NF-κB.

**MATERIALS AND METHODS**

**Cell Lines**

Drug-sensitive CCRF-CEM and MDR P-glycoprotein-overexpressing CEM/ADR5000 leukemic cells were kindly provided by Prof. Axel Sauerbrey (Department of Pediatrics, University of Jena, Germany). Cells were maintained in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin (1,000 U/mL)/streptomycin (100 µg/mL) (P/S) (Life Technologies, Darmstadt, Germany). Doxorubicin (5,000 ng/mL) was added to maintain overexpression of P-gp (MDR1 and ABCB1) in resistant cells (Kimmin et al., 1990). Human embryonic kidney cells (HEK293) were maintained in DMEM + GlutaMAX-I medium (Life Technologies, Darmstadt, Germany) with 10% FBS and 1% P/S. The generation of HEK293 derived HEK293-ABCBI cells has been reported (Kawanobe et al., 2012). Breast cancer cells transduced with a control vector (MDA-MB-231-pcDNA3) or with cDNA for the breast cancer resistance protein (BCRP; ABCG2 (MDA-MB-231-BCRP clone 23) were generated as reported (Doyle et al., 1998). The cell lines were maintained in 800 ng/mL genetin (Efferth et al., 2003; Saed et al., 2015). Cell lines used for cell viability assays are listed in Supplementary Table S1.
Cell Viability Assay
The cytotoxic effects of bromocriptine (Sigma-Aldrich, Taukirchen, Germany; Figure 7A) was evaluated by the resazurin assay (O’Brien et al., 2000). This assay is based on reduction of the indicator dye, resazurin, to the highly fluorescent resorufin by viable cells. Aliquots of 5,000 cells/100 µL of HEK293 and MDA-MB-231 were seeded in 96-well plates and incubated for one day before treatment. However, for leukemic cells, 10,000 cells/100 µL cells placed into 96-well plates and immediately treated. After 72 h incubation, 20 µL resazurin 0.01% w/v solution were added to each well, and the plates were incubated at 37°C for 4 h. Fluorescence was measured by an Infinite M2000 Proplate reader (Tecan, Crailsheim, Germany) using an excitation wavelength of 544 nm and an emission wavelength of 590 nm. Each experiment was done at least three times with six replicates each. The viability was analyzed based on a comparison with untreated cells. Fifty percent inhibition (IC_{50}) values indicate the drug concentrations required to inhibit 50% of cell proliferation and were calculated from a calibration curve by linear regression using Microsoft Excel (Kuete et al., 2016a,b).

A combination of 20 or 40% of the IC_{50} value of bromocriptine (2.4 and 4.8 µM) with different concentrations of doxorubicin or paclitaxel was used to treat CEM/ADR5000 cells.

Statistical Tests
The Loewe additivity model was applied to evaluate the synergism between bromocriptine and doxorubicin and also between bromocriptine and paclitaxel (Lee et al., 2007). In this model, the combination index (CI) was defined as CI = d1/D1 + d2/D2, where D1 and D2 were the doses of Drug 1 and Drug 2 that caused 50% inhibition of CEM/ADR5000 cell growth when used alone, d1 and d2 were the doses of Drug 1 and Drug 2 in combination, which can generate the same response. If the CI is equal, less than or more than 1, the combination dose (d1, d2) is termed as additive, synergistic, or antagonistic, respectively. The drug interaction was shown geometrically as isobologram.

Clonogenic Assay
Clonogenic assays were performed to test the ability of a single cell to grow into a colony after treatment as described before (Franken et al., 2006); 1 × 10^6 cells of Hek293, Hek293 ABCB5, MDA-MB-231-pcDNA, and MDA-MB-231-BCRP cells were seeded and after 4 h incubation, varying concentrations of bromocriptine were treated for 72 h. Cells were harvested after treatment and re-plated in 6-well plates immediately after treatment at cell concentrations estimated to yield 50–150 colonies/well. Then, cells were cultured for 12 days to allow for colony formation. Cells were fixed in 2% formaldehyde in PBS for 2 min and the stained with 0.5% crystal violet in dH2O for 30 min. Colonies were counted using Image J and survival fraction was determined as explained previously (Franken et al., 2006).

Assessment of the Mode of Action of Bromocriptine by Annexin V-PI Staining
Cells were treated with IC_{50} and 2 × IC_{50} of bromocriptine or with 10 and 20 µM doxorubicin for 72 h. Afterward, cells...
were analyzed by annexin V-PI double staining (Thermo Fisher, Darmstadt, Germany). Annexin V is an intracellular protein that calcium-dependently binds to phosphatidylserine (PS), which translocates from the intracellular leaflet of the plasma membrane to the external leaflet during early apoptosis. Propidium iodide (PI) is excluded by living or early apoptotic cells with intact membranes and stains late apoptotic and necrotic cells with red fluorescence due to DNA intercalation. Therefore, cells with annexin V (−) and PI (−) are considered to be alive, while cells with annexin V (+) and PI (−) are in early apoptosis. Cells in late apoptosis or necrosis are both annexin V and PI positive. Briefly, CCRF-CEM cells were treated with various concentrations of bromocriptine or doxorubicin for 72 h. After incubation, cells were collected by centrifugation. After washing with PBS, cells were incubated with annexin V and PI binding buffer (Thermo Fisher) according to the manufacturer’s protocol. Subsequently, $2 \times 10^4$ cells were counted and measured with Accuri™ C6 cytometer (BD Biosciences, Heidelberg, Germany).

![Figure 3](image-url)

**FIGURE 3** | Synergistic effects of bromocriptine with (A,B) doxorubicin or with (C,D) paclitaxel in CEM/ADR5000 cells as shown in (A,C) dose response curves and (B,D) dose-normalized isobolograms.

![Figure 4](image-url)

**FIGURE 4** | Analysis of cell death in CCRF-CEM cells induced by bromocriptine or doxorubicin. (A) Representative dot plots of flow cytometry analysis after treatment of CCRF-CEM cells with IC_{50} or 2 × IC_{50} of bromocriptine as well as 10 or 20 μM doxorubicin for 72 h. (B) The graph shows mean values ± SD of three independent experiments. Annexin V+/PI−: late necrosis, annexin V+/PI+: late apoptosis or early necrosis, and annexin V−/PI+: early apoptosis.
The annexin V-APC signal was measured with 640 nm excitation and detected using a 675/25 nm bandpass filter. The PI signal was analyzed with 488 nm excitation and detected using a 585/40 nm bandpass filter. All parameters were plotted on a logarithmic scale. Cytographs were analyzed using BD Accuri C6 software (BD Biosciences).

**COMPARE and Cluster Analyses of Microarray Data**

The mRNA microarray hybridization of the NCI cell lines has been reported at the NCI Web site\(^1\) (Scherf et al., 2000; Amundson et al., 2008). The cell lines of the NCI panel are shown in Supplementary Table S2. COMPARE analyses were carried out to produce rank ordered lists of genes expressed in the NCI cell lines. The detailed method as a tool to identify candidate genes for drug resistance and sensitivity has been previously reported (Wosikowski et al., 1997; Evans et al., 2008; Fagan et al., 2010; Effert et al., 2011). In order to obtain COMPARE rankings, a scale index of correlation coefficients (\(R\)-values) was created from \(\log_{10}\)IC\(_{50}\) values of test compounds and microarray-based mRNA expression values. Greater mRNA expression correlated with enhanced drug resistance in the standard COMPARE, whereas greater mRNA expression in cell lines indicated drug sensitivity in reverse COMPARE analyses. Pearson’s correlation test was applied to calculate significance values and rank correlation coefficients as a relative measure for the linear dependency of two variables.

For hierarchical cluster analyses, objects were classified by calculation of distances according to the closeness of between individual distances. All objects were assembled into cluster trees (dendrograms). Merging of objects with similar features leads to cluster formation, where the length of the branch indicates the degree of relation. Distances of subordinate cluster branches to superior cluster branches serve as criteria for the closeness of clusters. Therefore, objects with tightly related features were clustered closely together, while separation of objects in the dendrogram increased with progressive dissimilarity. Hierarchical clustering and heat map analyses were performed using clustered image map (CIM) miner software by the one matrix CIM\(^2\) (Weinstein et al., 1997).

**Molecular Docking**

Molecular docking was performed to predict the interaction energy of bromocriptine with target proteins: I-\(\kappa\)B kinase \(\beta\), I-\(\kappa\)B kinase \(\beta\)-NEMO complex, NF-\(\kappa\)B, and NF-\(\kappa\)B-DNA complex. The protocol for molecular docking was published by us (Zeino et al., 2014). Protein structures using X-ray crystallography were retrieved from PDB database\(^3\). I-\(\kappa\)B kinase \(\beta\) (PDB ID:3RZF), I-\(\kappa\)B kinase \(\beta\)-NEMO complex (PDB ID:3BRT), NF-\(\kappa\)B (p52/RelB heterodimer, PDB ID:3DO7), and NF-\(\kappa\)B-DNA complex (p50/p65 heterodimer bound to DNA, PDB ID:IVKX) were used in our study. A grid box was designed to define docking spaces in each protein according to its pharmacophores. Docking parameters were set to 250 runs and 2,500,000 energy evaluations for each time. Lamarckian genetic algorithm was chosen for docking calculations. For the visualization of docking results, AutodockTools-1.5.7rcl was used. The surface representation image showing the binding pocket of proteins was made with Visual Molecular Dynamics (VMD) software developed with NIH support by the Theoretical and Computational Biophysics group at NIH.

\(^1\)http://dtp.nci.nih.gov
\(^2\)https://discover.nci.nih.gov/cimminer/oneMatrix.do
\(^3\)http://www.rcsb.org/

**FIGURE 5** | Molecular docking studies of bromocriptine to NF-\(\kappa\)B pathway proteins. (A) Docking poses into the ATP binding site of IKK (PDB code: 3RZF in yellow surface representation). (B) Docking poses into the interaction site of the IKK (PDB code: 3BRT in blue surface representation). (C) Docking poses into the DNA binding site of NF-\(\kappa\)B (p52/RelB heterodimer, PDB code: 3DO7 in green cartoon representation). (D) Docking poses into the DNA binding site of the NF-\(\kappa\)B-DNA complex (p50/p65 heterodimer bound to DNA, PDB ID:IVKX) were used in our study. A grid box was designed to define docking spaces in each protein according to its pharmacophores. Docking parameters were set to 250 runs and 2,500,000 energy evaluations for each time. Lamarckian genetic algorithm was chosen for docking calculations. For the visualization of docking results, AutodockTools-1.5.7rcl was used. The surface representation image showing the binding pocket of proteins was made with Visual Molecular Dynamics (VMD) software developed with NIH support by the Theoretical and Computational Biophysics group at NIH.
the Beckman Institute, University of Illinois at Urbana-Champaign.

**NF-κB Reporter Cell Assay**

HEK293 cells stably expressing HEK-Blue-Null1 vector and SEAP on a NF-κB promoter were purchased from Invivogen (San Diego, CA, United States). The cells were cultured according to manufacturer's protocol and treated with several different concentrations of bromocriptine (0, 20, and 40 µM) for 1 h and bromocriptine was not removed. Afterward, NF-κB activity was induced with 100 ng/mL of TNF-α for 24 h. The activation was measured by detecting SEAP spectrophotometrically at 630 nm with addition of Quanti Blue (Invivogen). The procedure has been reported by us (Kadioglu and Efferth, 2015; Kadioglu et al., 2016; Dawood et al., 2018).

**RESULTS**

**Cytotoxicity of Bromocriptine Against ABC-Transporter Expressing Tumor Cell Lines**

The inhibition of drug-sensitive (CCRF-CEM, HEK293, and MDA-MB-231-pcDNA3) and MDR cell lines (CEM/ADR5000, HEK293-ABCB5, and MDA-MB-231-BCRP) by bromocriptine

| Protein                  | Lowest energy of docking (kcal/mol) | Mean binding energy (kcal/mol) | Residues involved hydrogen bond interaction with the ligand | Residues involved in hydrophobic interaction with ligand | pKi (nM) |
|--------------------------|-------------------------------------|--------------------------------|-------------------------------------------------------------|--------------------------------------------------------|----------|
| IκB kinase β             | −9.60 ± 0.20                        | −9.48 ± 0.27                   | -                                                           | LEU21, GLY22, THR23, VAL29, ALA42, TYR98, CYS99, GLU100, GLY102, ASP103, LYS147, GLU149, ASN150 VAL152 | 95.18 ± 33.56 |
| IκB kinase β             | −8.47 ± 0.01                        | −8.13 ± 0.07                   | GLY86                                                       | THR726, GLU729, GLN730, ASN732, GLN86, GLU89, LYS90, LEU93 | 620.91 ± 9.47 |
| NEMO                     | −8.47 ± 0.01                        | −8.13 ± 0.07                   | GLY86                                                       | THR726, GLU729, GLN730, ASN732, GLN86, GLU89, LYS90, LEU93 | 620.91 ± 9.47 |
| NF-κB                    | −9.02 ± 0.03                        | −8.47 ± 0.16                   | GLU245, GLU289                                             | CYS284, ARG285, ILE286, ASN287, LYS288, GLU289, LEU371, PRO372, ASP234, LYS235, ASP244, GLU245, TYR247 | 244.41 ± 11.98 |
| NF-κB DNA complex        | −11.13 ± 0.21                       | −10.51 ± < 0.00                | DT9                                                         | DC7, DT8, DT9, DT10, DA18, DG19, DT20, DC21, DC22, LYS122, ARG124 | 7.23 ± 2.64 |

Molecular defined dockings were performed with 250 runs for each protein.
was investigated using the resazurin assay. The growth of CEM/ADR5000, CCRF-CEM and HEK293 cells was inhibited by treatment with bromocriptine for 72 h. The IC_{50} values of bromocriptine toward CCRF-CEM and CEM/ADR5000 were 10.13 and 11.78 µM, respectively (Figure 1A). HEK293 cells were inhibited at concentrations of 5.24 µM of bromocriptine, while HEK/ABCB5 transfecteds were not inhibited by concentrations up to 100 µM (Figure 1B). To test BRCP as another member of the ABC-transporter family, MDA-MB-231 cells transfected with a cDNA coding for BRCP were treated with bromocriptine and compared to mock-vector transfected MDA-MB-231pcDNA3 cells. Bromocriptine did, however, not inhibit the growth of these two cell lines in concentrations up to 100 µM, indicating that bromocriptine was not active against these cell lines (Figure 1C).

Clonogenic Assays
Clonogenic assay results were comparable with the results of the resazurin assay. The surviving fraction (% of control) of Hek293 cells decreased after treatment with bromocriptine, whereas the surviving fraction of Hek293 ABCB5, MDA-MB-231-pcDNA, and MDA-MB-231-BCRP cells was not considerably affected (Figure 2).

Cytotoxic Effects of Combination of Bromocriptine With Doxorubicin or With Paclitaxel
We tested cytotoxic effects of combination of bromocriptine with doxorubicin or with paclitaxel. The combination of bromocriptine (20% IC_{50} and 40% IC_{50}) with doxorubicin or with paclitaxel resulted in synergistic effects in CEM/ADR5000 cells using the Loewe isobologram method (Figure 3).

Induction of Apoptosis by Bromocriptine in CCRF-CEM Cells
We investigated the action of bromocriptine by annexin V-PI staining (Figure 4). After treatment of CCRF-CEM cells with IC_{50} or 2 × IC_{50} concentrations of bromocriptine for 72 h, more than 15% of cells appeared in late apoptosis (annexin V+/PI+). Doxorubicin, which was used as cytotoxic control drug, caused dramatic induction of cell death with more than 70% cells in late apoptosis (annexin V+/PI+; Figure 4).

Inhibition of NF-κB by Bromocriptine
NF-κB represents an important mechanism to many anticancer drugs, because it can inhibit drug-induced apoptosis of chemotherapeutics (Baldwin, 2001; Wu and Bonavida, 2009; Darvishi et al., 2017). Therefore, we were interested to investigate the effect of bromocriptine on this transcription factor.

We first performed in silico molecular dockings, in order to evaluate the binding of bromocriptine to NF-κB pathway proteins. Interestingly, bromocriptine showed strong interactions with NF-κB pathway proteins (Figure 5 and Table 1). Bromocriptine showed stronger binding to the NF-κB-DNA complex as NF-κB alone. The binding energies were −11.13 ± 0.21 with the NF-κB-DNA complex and −9.02 ± 0.03 with NF-κB alone. Bromocriptine formed hydrogen bonds with bound DNA. The drug bound to the ATP-binding site of I-κB kinase β with a binding energy of −9.60 ± 0.20 kcal/mol. It also docked to the I-κB kinase β-NEMO interaction site with a binding energy of −8.47 ± 0.21 kcal/mol. Our molecular docking results indicated that bromocriptine strongly bound to NF-κB pathway proteins. Furthermore, binding affinity of bromocriptine was higher to DNA-bound NF-κB than to free NF-κB, indicating that bromocriptine may inhibit DNA binding.

Then, we performed NF-κB reporter cell in vitro assays to confirm the results obtained by molecular docking in silico. Bromocriptine inhibited NF-κB activity in a dose-dependent manner in the presence of 100 ng/mL TNFα as NF-κB-inducing agent (Figure 6).

Cytotoxicity of Bromocriptine Toward the NCI Cell Line Panel
Protein and mRNA expression as well as DNA mutations of ABC-transporters (ABCB1, ABCB5, ABCC1, and ABCG2) and other mechanisms of drug resistance (EGFR, mutated TP53, NFκB, and IκB) in the NCI cell line panel was correlated with the log_{10}IC_{50} values for bromocriptine. While statistically significant correlations were not found for bromocriptine (except for NF-κB), the log_{10}IC_{50} values of positive control drugs significantly correlated to their corresponding mechanisms of resistance (daunorubicin for ABCB1, mayansine, for ABCB5, vinblastine for ABC1, pancristatin for ABCG3, erlotinib for EGFR, 5-fluoruracil for mutated TP53, and parthenolide for I-κB; Table 2). This indicates that bromocriptine is not involved in the drug resistance profiles of these multiple drug resistance mechanisms.

Drug Class Profiling
To investigate the cross-resistance profile of the NCI cell lines to bromocriptine in more detail, we correlated bromocriptine's log_{10}IC_{50} values with those of 89 standard anticancer drugs. The response of 57% of the anti-hormonal drugs, 36% of the
## TABLE 2 | Correlation of log_{10}IC_{50} values for bromocriptine to drug resistance mechanisms (ABCB1, ABCB5, ABCC1, ABCG2, EGFR, TPS3, NF\(_\kappa\)B, and I\(_\kappa\)B) in the NCI cell line panel.

|                      | Bromocriptine (log10 IC50, M) | Control drug (log10 IC50, M) |
|----------------------|--------------------------------|---------------------|
| ABCB1 expression     | R-value                        | Daunorubicin        |
| 7q21 (Chromosomal)   | R-value                        | \(-0.071\)          |
| locus of ABCB1 gene  | P-value                        | \(0.305\)           |
| ABCB1 expression     | R-value                        | \(-0.097\)          |
| (Microarray)         | P-value                        | \(0.234\)           |
| ABCB1 expression     | R-value                        | \(-0.233\)          |
| (RT-PCR)             | P-value                        | \(0.052\)           |
| Rhodamine 123        | R-value                        | \(-0.095\)          |
| Accumulation         | P-value                        | \(0.241\)           |
| ABCB5 expression     | R-value                        | Maytansine          |
| (microarray)         | P-value                        | \(0.098\)           |
| ABCB5 expression     | R-value                        | \(0.234\)           |
| (RT-PCR)             | P-value                        | \(0.223\)           |
| ABCC1 expression     | R-value                        | \(-0.008\)          |
| (RT-PCR)             | P-value                        | \(0.480\)           |
| ABCG2 expression     | R-value                        | Vinblastine         |
| (Microarray)         | P-value                        | \(-0.213\)          |
| ABCG2 expression     | R-value                        | \(-0.280\)          |
| (Western blot)       | P-value                        | \(0.017\)           |
| EGFR expression      | R-value                        | \(-0.071\)          |
| Copy number          | P-value                        | \(0.132\)           |
| EGFR expression      | R-value                        | \(-0.020\)          |
| (Microarray)         | P-value                        | \(0.056\)           |
| EGFR expression      | R-value                        | \(0.439\)           |
| (RNAse protection)   | P-value                        | \(0.014\)           |
| EGFR expression      | R-value                        | \(0.458\)           |
| (Protein array)      | P-value                        | \(0.086\)           |
| TPS3 mutation        | R-value                        | \(0.2616\)          |
| TPS3 mutation        | R-value                        | \(-0.118\)          |
| (cDNA sequencing)    | P-value                        | \(0.190\)           |
| TPS3 function        | R-value                        | \(-0.103\)          |
| (Yeast functional assay) | P-value                       | \(0.232\)           |
| NF\(_\kappa\)B expressin NF\(_\kappa\)B expressin | R-value | \(0.309\) |
| (Microarray)         | P-value                        | \(0.001\)           |
| i\(_\kappa\)B expressin i\(_\kappa\)B expressin | R-value | \(-0.020\) |
| (Microarray)         | P-value                        | \(0.443\)           |

*\(P < 0.05\) and \(R > 0.3\) (or \(R < -0.3\)).

Tyrosine kinase inhibitors, 33% of the platinum compounds, 31% of the alkylating agents, 20% of various other drugs, and 7% of the anti-metabolites significantly correlated with bromocriptine (Figure 7C). The significant correlations between cellular response to bromocriptine and anti-hormonal anticancer drugs were found for fulvestrant, anastroz, megestrol, and raloxifene, but not tamoxifen, toremifen, and exemestane.

Typical drugs involved in ABC-transporter-mediated multidrug resistance phenotypes (e.g., DNA topoisomerase I or II inhibitors, taxanes, Vinca alkaloids, etc.) did not correlate...
We investigated the transcriptome-wide mRNA expression of the NCI cell lines by COMPARE analysis and correlated the microarray-based mRNA expression data set with the log_{10}IC_{50} values for bromocriptine in 60 cell lines of diverse tumor types, in order to identify novel putative factors associated with cellular response to this compound. The scale rankings of genes obtained by COMPARE computation were subjected to Pearson’s rank correlation tests. The top 20 genes with direct and the top 20 genes with inverse correlation coefficients are shown in Table 3.

The mRNA expression of these genes was subjected to hierarchical cluster analysis and cluster image mapping (Figure 8). The dendrogram with the cell lines illustrated at the left hand side of the heat map can be divided into four major clusters (Figure 8). We analyzed the distribution of cell lines for their sensitivity toward bromocriptine by the chi-square test (Table 4). The distribution of cell lines being sensitive or resistant was significantly different in the dendrogram showing that cellular response to bromocriptine was predictable by this set of mRNA expressions (Figure 8 and Table 4). Cluster 1 contained only sensitive, cluster 2 mainly sensitive, and clusters 3 and 4 mostly resistant cell lines. This distribution of sensitive and resistant cell lines was statistically significant (P = 7.03 × 10^{-5}). Interestingly, many of the identified genes code for ribosomal proteins (RPL9, RPS24, RPS3A, RPL34, RPS21, RPS27A, RPS15A, RPSA, RPL6, and RPL23A).

**DISCUSSION**

Bromocriptine is originally treated for Parkinson’s disease, acromegaly, hyperprolactinemia, galactorrhea, and more recently also for diabetes mellitus (Millan et al., 2002; Murteira et al., 2013). It acts as D1 and D2 dopamine receptor agonists, and as D4 dopamine receptor antagonist (Tan and Jankovic, 2001; Millan et al., 2002). Bromocriptine reduces tumor growth by inhibiting synthesis and secretion of prolactin and inhibiting angiogenesis in the tumor environment (Webster, 1999).

In our study, bromocriptine showed cytotoxic effects not only toward drug-sensitive CCRF-CEM, but also MDR P-glycoprotein overexpressing CEM/ADR5000 leukemic cells. Moreover, it was cytotoxic toward HEK293 cells, but only weakly active against HEK-ABCB5 transfectants. Comparable results were obtained by clonogenic assays.

Collateral sensitivity ( = hypersensitivity) is not infrequently seen in ABC-transporter-expressing cells. This phenomenon is known for many years in ABCB1 (P-gp/MDR1) and MRP1overexpressing tumor cells (Hutchison, 1963; Gottesman and Pastan, 1993). Therefore, it is straightforward also to expect drugs that exert collateral sensitivity in ABCB5-expressing cells. The phenomenon for ABCB5 is, however, new, and to the best of our knowledge, the results of the present data are the first. In this respect, the present data are novel.

Collateral sensitivity in other ABC-transporters is mostly caused by excessive consumption of ATP. The collateral sensitive drugs bind to the ABC-transporter. The transporter tries to pump out the drug under consumption of ATP. If this process fails, the transporter tries once more to pump out this molecules under ATP consumption. This process is repeated many times, and the ATP stores in the cells are consumed leading to the death of the cell. Since drug-sensitive wild-type cells do not express the ABC-transporter, this preferential ATP consumption does not take place and the cells are not preferentially killed. This leads to the somewhat paradox situation that MDR ABC-transporter

with bromocriptine (Figure 7C). This result confirmed the missing correlation of the cellular response of bromocriptine to ABC-transporter expression (Table 2).

**Tumor Type-Dependent Response to Bromocriptine**

If the average log_{10}IC_{50} values of the NCI cell line panel were diversified according to the tumor type of the cell lines, leukemia and colon carcinomas were most sensitive, whereas melanoma and brain tumors were most resistant to bromocriptine (Figure 7B).

**COMPARE and Hierarchical Cluster Analysis of mRNA Microarray Data**

We investigated the transcriptome-wide mRNA expression of the NCI cell lines by COMPARE analysis and correlated the microarray-based mRNA expression data set with the log_{10}IC_{50} values for bromocriptine in 60 cell lines of diverse tumor types, in order to identify novel putative factors associated with cellular response to this compound. The scale rankings of genes obtained by COMPARE computation were subjected to Pearson’s rank correlation tests. The top 20 genes with direct and the top 20 genes with inverse correlation coefficients are shown in Table 3. The mRNA expression of these genes was subjected to hierarchical cluster analysis and cluster image mapping (Figure 8). The dendrogram with the cell lines illustrated at the left hand side of the heat map can be divided into four major clusters (Figure 8). We analyzed the distribution of cell lines for their sensitivity toward bromocriptine by the chi-square test (Table 4). The distribution of cell lines being sensitive or resistant was significantly different in the dendrogram showing that cellular response to bromocriptine was predictable by this set of mRNA expressions (Figure 8 and Table 4). Cluster 1 contained only sensitive, cluster 2 mainly sensitive, and clusters 3 and 4 mostly resistant cell lines. This distribution of sensitive and resistant cell lines was statistically significant (P = 7.03 × 10^{-5}). Interestingly, many of the identified genes code for ribosomal proteins (RPL9, RPS24, RPS3A, RPL34, RPS21, RPS27A, RPS15A, RPSA, RPL6, and RPL23A).

**DISCUSSION**

Bromocriptine is originally treated for Parkinson’s disease, acromegaly, hyperprolactinemia, galactorrhea, and more recently also for diabetes mellitus (Millan et al., 2002; Murteira et al., 2013). It acts as D1 and D2 dopamine receptor agonists, and as D4 dopamine receptor antagonist (Tan and Jankovic, 2001; Millan et al., 2002). Bromocriptine reduces tumor growth by inhibiting synthesis and secretion of prolactin and inhibiting angiogenesis in the tumor environment (Webster, 1999).

In our study, bromocriptine showed cytotoxic effects not only toward drug-sensitive CCRF-CEM, but also MDR P-glycoprotein overexpressing CEM/ADR5000 leukemic cells. Moreover, it was cytotoxic toward HEK293 cells, but only weakly active against HEK-ABCB5 transfectants. Comparable results were obtained by clonogenic assays.

Collateral sensitivity ( = hypersensitivity) is not infrequently seen in ABC-transporter-expressing cells. This phenomenon is known for many years in ABCB1 (P-gp/MDR1) and MRP1overexpressing tumor cells (Hutchison, 1963; Gottesman and Pastan, 1993). Therefore, it is straightforward also to expect drugs that exert collateral sensitivity in ABCB5-expressing cells. The phenomenon for ABCB5 is, however, new, and to the best of our knowledge, the results of the present data are the first. In this respect, the present data are novel.

Collateral sensitivity in other ABC-transporters is mostly caused by excessive consumption of ATP. The collateral sensitive drugs bind to the ABC-transporter. The transporter tries to pump out the drug under consumption of ATP. If this process fails, the transporter tries once more to pump out this molecules under ATP consumption. This process is repeated many times, and the ATP stores in the cells are consumed leading to the death of the cell. Since drug-sensitive wild-type cells do not express the ABC-transporter, this preferential ATP consumption does not take place and the cells are not preferentially killed. This leads to the somewhat paradox situation that MDR ABC-transporter

with bromocriptine (Figure 7C). This result confirmed the missing correlation of the cellular response of bromocriptine to ABC-transporter expression (Table 2).

**Tumor Type-Dependent Response to Bromocriptine**

If the average log_{10}IC_{50} values of the NCI cell line panel were diversified according to the tumor type of the cell lines, leukemia and colon carcinomas were most sensitive, whereas melanoma and brain tumors were most resistant to bromocriptine (Figure 7B).

**COMPARE and Hierarchical Cluster Analysis of mRNA Microarray Data**

We investigated the transcriptome-wide mRNA expression of the NCI cell lines by COMPARE analysis and correlated the microarray-based mRNA expression data set with the log_{10}IC_{50} values for bromocriptine in 60 cell lines of diverse tumor types, in order to identify novel putative factors associated with cellular response to this compound. The scale rankings of genes obtained by COMPARE computation were subjected to Pearson’s rank correlation tests. The top 20 genes with direct and the top 20 genes with inverse correlation coefficients are shown in Table 3. The mRNA expression of these genes was subjected to hierarchical cluster analysis and cluster image mapping (Figure 8). The dendrogram with the cell lines illustrated at the left hand side of the heat map can be divided into four major clusters (Figure 8). We analyzed the distribution of cell lines for their sensitivity toward bromocriptine by the chi-square test (Table 4). The distribution of cell lines being sensitive or resistant was significantly different in the dendrogram showing that cellular response to bromocriptine was predictable by this set of mRNA expressions (Figure 8 and Table 4). Cluster 1 contained only sensitive, cluster 2 mainly sensitive, and clusters 3 and 4 mostly resistant cell lines. This distribution of sensitive and resistant cell lines was statistically significant (P = 7.03 × 10^{-5}). Interestingly, many of the identified genes code for ribosomal proteins (RPL9, RPS24, RPS3A, RPL34, RPS21, RPS27A, RPS15A, RPSA, RPL6, and RPL23A).
### TABLE 3

Correlation of mRNA expression of genes identified by COMPARE analysis with log_{10}IC_{50} values of bromocriptine for 60 NCI tumor cell lines.

| COMPARE coefficient | Pattern ID | GeneBank accession | Gene symbol | Gene name | Gene function |
|---------------------|------------|---------------------|-------------|-----------|---------------|
| 0.642               | GC38764    | X60489              | EEF1B2      | Eukaryotic translation elongation factor 1β2 | Stimulates the exchange of GDP bound to EF1α to GTP |
| 0.640               | GC39380    | U09953              | RPL9        | Ribosomal protein L9 | Required for processing of pre-rRNA and maturation of 40S ribosomal subunits |
| 0.627               | GC35297    | M31520              | RPS24       | Ribosomal protein S24 | |
| 0.622               | GC33697    | M84711              | RPS3A       | Ribosomal protein S3A | Role during erythropoiesis by regulation of transcription factor DDIT3 |
| 0.616               | GC29122    | AF054183            | RAN         | RAN, member RAS oncogene family | Mediation of nucleocytoplasmic protein and ribonucleoprotein transport |
| 0.612               | GC36652    | L38941              | RPL34       | Ribosomal protein L34 | 60S ribosomal protein L34 |
| 0.604               | GC34926    | X79663              | RPS21       | Ribosomal protein S21 | 40S ribosomal protein S21, 9 kDa |
| 0.598               | GC37574    | S79522              | RPS27A      | Ribosomal protein S27a | 60S ribosomal protein S27A. Component of the 40S subunit of the ribosome |
| 0.596               | GC30163    | AF054187            | NACA        | Nascent polypeptide-associated complex α subunit | Regulation of myotube development. Role in ventricular cardiomyocyte expansion and postnatal skeletal muscle growth and regeneration |
| 0.593               | GC37319    | W52024              | RPS15A      | Ribosomal protein S15a | 60S ribosomal protein S15A |
| 0.592               | GC34223    | M14199              | RPSA        | Ribosomal protein S4A | Required for the assembly and stability of the 40S ribosomal subunit. Cell surface receptor for laminin. Cell adhesion to the basement membrane and activation of signaling transduction |
| 0.590               | GC36135    | X99226              | FANCA       | Fanconi anemia, complementation group A | Interstrand DNA cross-link repair and maintenance of chromosome stability |
| 0.585               | GC28763    | AF016371            | PPIH        | Peptidylprolyl isomerase H (cyclophilin H) | Protein folding |
| 0.576               | GC30155    | Z23064              | RBMX        | RNA binding motif protein, X-linked | Regulation of gene transcription and alternative splicing of several pre-mRNAs |
| 0.575               | GC29002    | M14630              | PTMA        | Prothymosin α | Mediation of immunological resistance to certain opportunistic infections |
| 0.574               | GC34930    | X69391              | RPL6        | Ribosomal protein L6 | Specifically binds to domain C of the tax-responsive enhancer element in the long terminal repeat of HTLV-I |
| 0.571               | GC27651    | AB007191            | MYCBP       | C-myc binding protein | May control the transcriptional activity of MYC. Stimulates the activation of E box-dependent transcription by MYC |
| 0.571               | GC29848    | T79616              | UQCRB       | Ubiquinol-cytochrome c reductase binding protein | A component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain |
| 0.570               | GC35323    | U37230              | RPL23A      | Ribosomal protein L23a | Binds 26S rRNA |
| 0.567               | GC35222    | TARDBP              | AL050265    | TAR DNA binding protein | DNA and RNA-binding protein regulating transcription and splicing |
| –0.612              | GC33001    | U11872              | CXCR2       | Chemokine (C-X-C motif) receptor 2 | IL8 receptor activating neutrophils |
| –0.546              | GC35931    | X13255              | DBH         | Dopamine β-hydroxylase (dopamine β-monooxygenase) | Activity is enhanced by nerve growth factor |
| –0.545              | GC27591    | D87463              | PHYHHP      | Phytanoyl-CoA 2-hydroxylase interacting protein | Role in the development of the central system |
| –0.544              | GC28151    | U15780              | ST5         | Suppression of tumorigenicity 5 | Guanine nucleotide exchange factor (GEF) activating RAB9A and RAB9B |

(Continued)
TABLE 3 | Continued

| COMPARE coefficient | Pattern ID | GeneBank accession | Gene symbol | Gene name | Gene function |
|---------------------|------------|--------------------|-------------|-----------|---------------|
| −0.516              | GC31384    | AF035812           | DYNC1L2     | Dynein, cytoplasmic 1, light intermediate chain 2 | Component of the cytoplasmic dynein 1 complex that is involved cargo transport |
| −0.495              | GC29420    | Z50022             | PTTG1P      | Pituitary tumor-transforming 1 interacting protein | Facilitates PTTG1 nuclear translocation by transcription factor RUNK2 |
| −0.479              | GC30117    | W27517             | TMEM109     | Transmembrane protein 109 | DNA damage response. Protection against ultraviolet C-induced cell death |
| −0.476              | GC38293    | M33680             | CD81        | Cluster of differentiation molecule 81 | Signal transducer. Viral receptor for HCV |
| −0.476              | GC29175    | AA487755           | FKBP9       | FK506 binding protein 9, 63 kDa | Protein folding during protein synthesis |
| −0.476              | GC36401    | AB023151           | DIP2C       | DIP2 disco-interacting protein 2 homologue C (Drosophila) | Transcription factor binding |
| −0.474              | GC31394    | AB011171           | PLEKHG3     | Pleckstrin homology domain containing, family G (with RhoGef domain) member 3 | Rho guanyl-nucleotide exchange factor |
| −0.474              | GC38796    | AF035292           | OBESL1      | Obscurin-like 1 | Role in the ubiquitin ligase pathway that regulates Golgi morphogenesis and dendrite patterning in brain |
| −0.473              | GC33621    | Y00285             | IGF2R       | Insulin-like growth factor 2 receptor | Transport of phosphorylated lysosomal enzymes from Golgi complex and cell surface to lysosomes |
| −0.472              | GC36838    | R48209             | FAM214B     | Family with sequence similarity 214 member B | Function unknown |
| −0.470              | GC35831    | AF104913           | EIF4G1      | Eukaryotic translation initiation factor 4y1 | Component of the eIF4F complex, which is involved in the recruitment of mRNA to the ribosome |
| −0.469              | GC32200    | AL096879           | TMEM184B    | Transmembrane protein 184B | Activation of MAP kinase signaling |
| −0.467              | GC31388    | S80562             | CNN3        | Calponin 3, acidic | Thin filament-associated protein modulating smooth muscle contraction. Binds actin, calmodulin, troponin C, and tropomyosin |
| −0.465              | GC32482    | M31724             | PTPN1       | Protein tyrosine phosphatase, non-receptor type 1 | Role in CKII- and p85α-induced signal transduction cascades. Regulation of EFN5-EPHA3 signaling, which modulates cell reorganization and cell-cell repulsion. Regulation of hepatocyte growth factor receptor signaling by MET dephosphorylation |
| −0.461              | GC32085    | AB018333           | SASH1       | SAM and SH3 domain containing 1 | Signal transducer, tumor suppressor |
| −0.459              | GC32336    | X07767             | PRKACA      | Protein kinase, cAMP-dependent, catalytic, α | Phosphorylation of cytoplasmic and nuclear proteins |

*Positive correlation coefficients indicated direct correlations to log_{10} IC_{50} values; negative ones indicated inverse correlations. Information on gene functions was taken from the OMIM database, NCI, United States (http://www.ncbi.nlm.nih.gov/Omim/) and from the GeneCard database of the Weizman Institute of Science, Rehovot Israel (https://www.genecards.org/).

expressing cells are more sensitive to some drugs than the wild-type counterparts not expressing ABC-transporters. It can be assumed that this process might also takes place in ABCB5-expressing cells.

The combination of bromocriptine (20% IC_{50} and 40% IC_{50}) with doxorubicin or with paclitaxel showed synergistic growth inhibition of CEM/ADR5000 cells. Our results are comparable with a previous report, which showed that bromocriptine reversed P-glycoprotein-mediated multidrug resistance in tumor cells (Shiraki et al., 2002). The authors showed that bromocriptine at 10 µM reduced the IC_{50} of doxorubicin in K562 cells from 9,000 to 270 ng/mL and that of vincristine in K562 from 700 to 0.30 ng/mL (Shiraki et al., 2002).

In the NCI cell line panel, the cellular response to bromocriptine was not associated with expression of ABC-transporters (ABCB1, ABCB5, ABCC1, and ABCG2) and other drug resistance mechanisms (EGFR, mutated TP53, and IκB). However, a significant correlation was found to NF-κB. Hence, bromocriptine may have the potential to inhibit otherwise drug-resistant tumors in a prolactin-independent manner. NF-κB may, however, be a resistance mechanisms for bromocriptine. This result was also confirmed by our
molecular docking data. Therefore, it is worth to consider bromocriptine for repurposing in cancer therapy. Repurposing of drugs may allow to shorten the long time to approval to the market, which is required for the development of novel drugs, thus, saving time and costs (Ashburn and Thor, 2004).

A practical consideration is, whether the bromocriptine concentration necessary to inhibit tumor growth can be reached in patients. While the serum levels of bromocriptine reached in psychotherapy (8 ng/mL) may too low to exert cytotoxic effects against cancer cells, a number of publications report on the successful treatment of cancer patients with bromocriptine. This indicates that higher doses are applicable leading to significant reductions of tumor growth in the clinical setting. Thirty infertile women with prolactinoma were treated with 2.5–20 mg/day bromocriptine. After treatment for 24 months, prolactin and tumor diameter were significantly reduced (Hajder et al., 2013). Ten women with metastatic breast cancer and 10 men with metastatic prostate cancer were treated with 2.5 mg p.o. for 24 h, which led to a normalization of prolactin levels in all patients (Lissoni et al., 2000). A clinical phase 2 trial with progressive metastatic prostate cancer revealed that prolactin was suppressed in 10 of 11 patients without serious side effects upon treatment with 3 × 2.5 mg/day bromocriptine (Horti et al., 1998). Breast

TABLE 4 | Separation of clusters of NCI cell lines obtained by hierarchical cluster analyses for bromocriptine shown in Figure 5.

|          | Sensitive | Resistant |
|----------|-----------|-----------|
| Partition| ≤−4.418   | >−4.418   |
| Cluster 1| 6         | 0         |
| Cluster 2| 18        | 6         |
| Cluster 3| 5         | 17        |
| Cluster 4| 1         | 6         |
| Chi-square test | $P = 7.13 \times 10^{-5}$ |
cancer patients showed significantly reduced prolactin levels and less tumor cells in the S-phase of the cell cycle upon treatment with 1.25–2.5 mg bromocriptine for 5 days (Fentiman et al., 1988). In our study, 20–100 µM were used to induce cytotoxicity and inhibit NF-κB activation. Further studies are warranted to find the best suited doses of bromocriptine to inhibit tumors in vivo and in the clinic.

Our drug profiling approach with 89 standard anticancer drugs revealed that the NCI cell line panel did not show any correlations between response to bromocriptine and cytostatic drugs that are usually involved in ABC-transporter-mediated multidrug resistance phenotypes, e.g., anthracyclines, epipodophyllotoxins, camptothecins, Vinca alkaloids, taxanes, etc. This result fits together with the missing correlations of log_{10}IC_{50} values for bromocriptine and mRNA and protein expression of ABC-transporters. This was also true for factors that confer not only oncogenic signals, but also resistance to cytostatic drugs, i.e., overexpression of the oncogene EGFR and mutation of the tumor suppressor gene TP53. Hence, bromocriptine is not involved in major drug resistance mechanisms and may therefore be attractive as alternative to treat refractory and otherwise resistant tumors.

Interestingly, we observed significant correlations between cellular response to bromocriptine and anti-hormonal anticancer drugs, i.e., fulvestrant, anastrozol, megestrol, and raloxifene. We suggest that the anti-prolactin activity of bromocriptine may share partwise common signal routes with these anti-hormonal drugs.

Furthermore, we investigated molecular determinants of sensitivity and resistance of 60 tumor cell lines using COMPARE analysis of microarray-based transcriptome-wide mRNA expression levels of these cell lines (Scherf et al., 2000). Genes from various functional groups such as ribosomal proteins, transcription, translation, DNA repair, DNA damage, protein folding, mitochondrial respiratory chain, and chemokine were detected in our COMPARE analysis. Interestingly, we identified that several genes for ribosomal proteins were upregulated (RPL9, RPS24, RPS3A, RPL34, RPS21, RPS27A, RPS15A, RPSA, RPL6, and RPL23A). Heterozygous inactivating mutations in ribosomal protein genes are related to hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans (Ajore et al., 2017).

The anti-AML cytotoxic effect of bromocriptine was shown by D4 dopamine receptor antagonism and other alternative mechanisms (Sachlos et al., 2012). It decreased tumor size by inhibiting the synthesis and secretion of prolactin, and inhibiting angiogenesis in the surrounding tissue (Schettini et al., 1988; Webster, 1999; Acharya et al., 2010). Furthermore, bromocriptine triggered apoptosis in leukemic cells (Liberante et al., 2016).

Cluster analyses were performed to predict, whether a cancer cell line is sensitive or resistant to a cytotoxic compound (Sertel et al., 2012). In our study, all clusters in Table 4 contained sensitive cells lines. However, the distribution differed significantly among the different clusters. The portion of sensitive cells in clusters 1 and 2 was much higher that in clusters 3 and 4. Vice versa, the portion of resistant cell lines in clusters 3 and 4 was much higher than in clusters 1 and 2. Cluster 1 contained 100% sensitive cell lines and 0% resistant cells. Cluster 2 contained 75% sensitive cells and 25% resistant cell lines. Cluster 3 contained 23% sensitive cell lines and 77% resistant cell lines. Cluster 4 contained 14% sensitive cell lines and 86% resistant cell lines. This percentage-based distribution clearly showed significant differences between the clusters as confirmed by the chi square test (p = 7.3 × 10^{-5}). Bromocriptine showed two clusters with predominantly sensitive and two clusters with predominately resistant cell lines. The prediction of sensitivity or resistance to cytotoxic drugs by mRNA expression profiles can be useful for individualized or precise drugs, since it might provide a chance to know whether a tumor will respond to specific drugs or not.

NF-κB mediates resistance toward diverse cancer therapeutics by inhibition of apoptosis, and inhibition of NF-κB sensitizes cancer cells toward anticancer drugs (e.g., doxorubicin and imatinib), cytotoxic phytochemicals (e.g., curcumin), biological agents (e.g., β-IFN and TRAIL), and radiation (Schwartz et al., 1999; Deeb et al., 2004; Bednarski et al., 2008; Chen et al., 2008; Choi et al., 2008; Loumamas et al., 2009; Tracey et al., 2010). Therefore, NF-κB can be an important target for drug development. We performed molecular docking analyses to study the binding of bromocriptine to NF-κB, I-κB kinase β, I-κB kinase β–NEMO complex, and NF-κB-DNA complex in silico. Our docking study showed that bromocriptine strongly binds to target proteins and it interacted more strongly with DNA-bound NF-κB than free NF-κB, indicating that bromocriptine can inhibit the DNA binding to NF-κB. We demonstrated that bromocriptine decreases NF-κB activity by SEAP-driven NF-κB reporter assay.

Our results indicate that bromocriptine can be further investigated as an anticancer repurposing drug.

**AUTHOR CONTRIBUTIONS**

E-JS performed cell viability assay, molecular dockings, cluster analyses of microarray data, and NF-κB reporter cell assay and wrote the manuscript. YS generated the ABCB5 transfected cell line. HG wrote and corrected the manuscript. TE organized this study, performed compare and cluster analyses of microarray data, and wrote the manuscript.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2018.01030/full#supplementary-material
REFERENCES

Acharya, S. V., Gopai, R. A., Menon, P. S., Bandgar, T. R., and Shah, N. S. (2010). Giant prolactinoma and effectiveness of medical management. Endocr. Pract. 16, 42–46. doi: 10.4158/EP090221.OR

Ajrore, R., Raiser, D., McConkey, M., Joud, M., Boidol, B., Mar, R., et al. (2017). Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. EMBO Mol. Med. 9, 498–507. doi: 10.15252/emmm.201606660

Amundson, S. A., Do, K. T., Vinikoor, L. C., Lee, R. A., Koch-Paiz, C. A., Ahn, J., et al. (2008). Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res. 68, 415–424. doi: 10.1158/0008-5472.CAN-07-1120

Ashburn, T. T., and Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683. doi: 10.1038/nrd1468

Baldwin, A. S. (2001). Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107, 241–246. doi: 10.1172/JCI11991

Bednarski, B. K., Ding, X., Coombe, K., Baldwin, A. S., and Kim, H. J. (2008). Active pharmacology. J. Cytol. Histol. 2, 80–92. doi: 10.4172/2151-9638.1000021

Deeb, D., Jiang, H., Gao, X., Hafner, M. S., Wong, H., Divine, G., et al. (2004). Arsenic and breast cancer: a preclinical study. Cancer Lett. 201, 213–219. doi: 10.1016/j.canlet.2003.09.026

Defronzo, R. A. (2009). Banting Lecture. From the triumvirate to the ominous management of prolactinomas. J. Clin. Endocrinol. Metab. 94, 2412–2419. doi: 10.1210/jc.2008-1936

Efferth, T., Sauerbrey, A., Olbrich, A., Gebhart, E., Rauch, P., Weber, H. O., et al. (2003). Molecular modes of action of arsunate in tumor cell lines. Mol. Pharmacol. 64, 382–394. doi: 10.1124/mol.64.2.382

Evans, A., Bates, V., Troy, H., Hewitt, S., Holbeck, S., Chung, Y. L., et al. (2008). Glut-1 as a therapeutic target: increased chemoresistance and HIF-1α-independent link with cell turnover is revealed through COMPARSE analysis and metabolicol studies. Cancer Chemother. Pharmacol. 61, 377–393. doi: 10.1007/s00280-007-0480-1

Ezroghi, Luo, S., Trubitsyna, Y., and Cincotta, A. H. (2014). Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol. Metab. Syndr. 6:104. doi: 10.1186/1758-5996-6-104

Fagan, V., Sarah, B., Michael, P. C., and Fawaz, A. (2010). One-pot double intramolecular homolytic aromatic substitution routes to dialicyclic ring fused imidazobenzimidazoquinolines and preliminary analysis of anticancer activity. Org. Biomol. Chem. 8, 3149–3156. doi: 10.1039/c003511d

Fentiman, I. S., Chaudary, M. A., Wang, D. Y., Brame, K., Campilho, R. S., and Millis, R. R. (1988). Perioperative bromocriptine adjuvant treatment for operable breast cancer. Lancet 1, 609–610. doi: 10.1016/S0140-6736(88)91413-4

Franken, N. A., Hans, M. R., Jan, S., Jaap, H., Chris, and van, B. (2006). Cytokine assay of cells in vitro. Nat. Protoc. 1, 2313–2319. doi: 10.1038/nprot.2006.339

Goldstein, M. (1980). Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects. Advances in Biochemical Psychopharmacology, New York, NY: Raven Press. 413–415

Gottesman, M. M., and Pastan, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385–427. doi: 10.1146/annurev.biol.62.070193.002125

Hajder, M., Hajder, E., Dervisefendic, M., Samardzic, R., and Alic, E. (2013). Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine. Med. Arch. 67, 181–184. doi: 10.5455/medarch.2013.67.181-184

Hayden, M. S., and Gosh, S. (2008). Shared principles in NF-kappaB signaling. Cell 132, 344–362. doi: 10.1016/j.cell.2008.01.020

Horti, J., Figg, W. D., Weinberger, B., Kohler, D., and Sartor, O. (1998). A phase II study of bromocriptine in patients with androgen-independent prostate cancer. Oncol. Rep. 5, 893–896. doi: 10.3892/or.5.4.893

Hutchison, D. J. (1963). Cross resistance and collateral sensitivity studies in cancer chemotherapy. Adv. Cancer Res. 7, 235–250. doi: 10.1016/S0065-230X(08)69848-7

Kadioglu, O., and Efferth, T. (2015). Pharmacogenomic characterization of cytotoxic compounds from Salvia officinalis in cancer cells. J. Nutr. Prod. 78, 762–775. doi: 10.1016/S0021-8229(04)00360-7

Kadioglu, O., Jacob, S., Bohnert, S., Nafl, J., Saeed, M. E., Khalid, H., et al. (2016). Pharmacogenomic characterization of cytotoxic compounds from Annona muricata L. as anti-cancer agents. EMBO Mol. Med. 9, 1808–1819. doi: 10.15252/emmm.201606660

Kawanobe, T., Kogure, S., Nakamura, S., Sato, M., Katayama, K., Tsuchiya, J., et al. (2012). Expression of human ABCB5 confers resistance to taxanes and anthracyclines. Biochem. Biophys. Res. Commun. 418, 736–741. doi: 10.1016/j.bbrc.2012.01.090

Kimmig, A., Gekeler, V., Neumann, M., Frese, G., Handgretinger, R., and Kardos, G. (1990). Susceptibility of multidrug-resistant human leukemia cell lines to anthracyclines. Biochem. Biophys. Res. Commun. 178, 787–794. doi: 10.1016/0006-291X(91)90517-2

Knezevic, E., Dean, M. W., and Efferth, T. (2016). Cytotoxicity of methanol extracts of Annona muricata L. towards cancer cells in human liver microvesSEL cultures. Int. J. Mol. Sci. 17, 1253–1272. doi: 10.3390/ijms17071253

Kuwert, T., Hartter, S., and Burger, E. (2006). A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin. Ther. 28, 1065–1078. doi: 10.1016/j.clinthera.2006.08.004
Lee, J. J., Maiying, K., Gregory, D. A., and Roni, L. (2007). Interaction index and different methods for determining drug interaction in combination therapy. J. Biopharm. Stat. 17, 461–480. doi: 10.1080/10543400701199593
Liberante, F. G., Pouryrahy, T., McMullin, M. F., Zhang, S. D., and Mills, K. I. (2016). Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget 7, 6609–6619. doi: 10.18632/oncotarget.6773
Lissoni, P., Mandal, M., Giani, L., Malugani, F., Secondino, S., Zonato, S., et al. (2000). Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancer-related hyperprolactinemia. Neuro Endocrinol. Lett. 21, 405–408.
Lounnas, N., Frelin, C., Gonthier, N., Colosetti, P., Sirvent, A., Cassuto, J. P., et al. (2009). NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int. J. Cancer 125, 308–317. doi: 10.1002/ijc.24294
Meier, A. H., Cincotta, A. H., and Lovell, W. C. (1992). Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Exp.eriencing 48, 248–253. doi: 10.1007/BF01930467
Millan, M. J., Maiofiss, L., Cussac, A., Audinot, V., Boutin, J. A., and Newman-Tancred, A. (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 305, 791–804. doi: 10.1124/jpet.1.059867
Morgan, M. J., and Liu, Z. G. (2011). Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 21, 103–115. doi: 10.1038/cr.2010.178
Muralikrishnan, D., and Mohanakumar, K. P. (1998). Neuroprotection by bromocriptine against multidrug-resistant tumor cells as selectively target cancer stem cells. J. Mark. Access Health Policy 1, 1–20. doi: 10.149, 1284ñ1297. doi: 10.1016/j.cell.2012.01.066.x
O’Brien, J., Wilson, I., Orton, T., and Pogman, F. (2000). Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267, 5421–5426. doi: 10.1046/j.1432-1327.2000.01606.x
Piil, H., Ohashi, S., Matsuda, M., Miyazaki, Y., Mahankali, A., Kumar, V., et al. (2000). Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23, 1154–1161. doi: 10.2337 diacare.23.8.1154
Radad, K., Gille, G., and Rausch, W. D. (2005). Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol. Rep. 57, 701–712.
Rivero-Segura, N. A., Flores-Soto, E., de la Cadena, S. G., Coronado-Mares, I., Sandoval, D., Cota, D., and Seeley, R. J. (2008). The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation. Annu. Rev. Physiol. 70, 513–535. doi: 10.1146/annurev.physiol.70.120806.095256
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., et al. (2000). A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236–244. doi: 10.1038/7439
Schettini, G., Lombardi, G., Merola, B., Milettio, P., Fariello, C., Cirillo, S., et al. (1988). Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas. J. Endocrinol. Invest. 11, 47–51. doi: 10.1007/BF03350096
Schwartz, S. A., Hernandez, A., and Mark Evers, B. (1999). The role of NF-kappab/lkappab proteins in cancer: implications for novel treatment strategies. Surg. Oncol. 8, 143–153. doi: 10.1016/S0960-7404(00)00012-8
Sertel, S., Eichhorn, T., Sieber, S., Sauer, A., Weiss, J., Plinkert, P. K., et al. (2012). Factors determining sensitivity and resistance of tumor cells to arsenic trioxide. PLoS One 7:e35584. doi: 10.1371/journal.pone.0035584
Shiraki, N., Okamura, K., Tokunaga, J., Ohmura, T., Yasuda, K., Kawaguchi, T., et al. (2002). Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells. Jpn. J. Cancer Res. 93, 209–215. doi: 10.1111/j.1349-7006.2002.tb01260.x
Tan, E. K., and Jankovic, J. (2001). Choosing dopamine agonists in Parkinson’s disease. Clin. Neuroropharmacol. 24, 247–253. doi: 10.1097/00028262-200109000-00001
Torner, L., Toschi, N., Pohlinger, A., Landgraf, R., and Id., (2001). Anxiolytic and anti-stress effects of brain prolactin: improved efficacy of antisense targeting of the prolactin receptor by molecular modeling. J. Neurosci. 21, 3207–3214. doi: 10.1523/JNEUROSCI.21-09-03207.2001
Tracey, L., Streck, C. J., Du, Z., Williams, R. F., Pfeffer, L. M., Nathwani, A. C., et al. (2010). NF-kappaB activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia. Leukemia 24, 806–812. doi: 10.1038/leuk.2010.2
Webster, J. (1999). Dopamine agonist therapy in hyperprolactinemia. J. Reprod. Med. 44(Suppl. 12), 1105–1110.
Weil, C. (1986). The safety of bromocriptine in long-term use: a review of the literature. Curr. Med. Res. Opin. 10, 25–51. doi: 10.1185/0300798609111089
Weinstein, J. N., Myers, T. G., O’Connor, P. M., Friend, S. H., Fojo, T., Kohn, K. W., et al. (1997). An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343–349. doi: 10.1126 science.275.5298.343
Wosikowski, K., Schuurhuis, D., Johnson, K., Paull, K. D., Myers, T. G., Weinstein, J. N., et al. (1997). Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J. Natl. Cancer Inst. 89, 1505–1515. doi: 10.1093/jnci/89.20.1505
Wu, K., and Bonavida, B. (2009). The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit. Rev. Immunol. 29, 241–254. doi: 10.1615/CritRevImmunol.v29.i3.40
Yoshikawa, T., Minamiyama, Y., Naito, Y., and Kondo, M. (1994). Antioxidant properties of bromocriptine, a dopamine agonist. J. Neurochem. 62, 1034–1038. doi: 10.1046/j.1471-4159.1994.62031034.x
Zeino, M., Saeed, M. E., Kadioglu, O., and Effерт, T. (2014). The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter. Invest. New Drugs 32, 618–625. doi: 10.1007/s10637-014-0098-1

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Sea, Sugimoto, Greten and Effерт. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.